Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The possibility of using the new drug eluting stents (DES) technology has significantly
changed the mid-term outcome of percutaneous coronary interventions (PCI) in terms of reduced
recurrence of angina. The way interventionalists accomplish their work is changing
accordingly, with a strong trend to a wider use of DES and a consequent perceived patients'
clinical benefit.
Evidences supporting the superiority of DES in reducing ischemic recurrence after PCI
compared to traditional stents (BMS) are available from randomized studies. A recent
meta-analyses underlines that:
DES are superior to BMS in reducing clinical recurrence of ischemia, DES and BMS offer
identical results in terms of death and infarction, Rapamycin and paclitaxel DES offer
similar results.
The aim of our study is to perform a multicenter, randomized study to assess the clinical
efficacy and safety of the oral prednisone therapy after PCI as a possible systemic
alternative to currently available BMS and DES. Furthermore, the study aims at analyzing the
clinical outcome of the commercially available DES in the context of an independent research
and a cost-benefit comparison with BMS and oral steroids.